Search

Adverum's ixo-vec, a gene therapy for wet AMD, has demonstrated a reduction in treatment burden and maintained visual acuity in a phase 2 study. [ABSTRACT FROM AUTHOR]

4DMT linked its gene therapy to a 90% reduction in treatment burden in wet AMD, emboldening it to start planning to enter phase 3 next year. [ABSTRACT FROM AUTHOR]

Frazier, RA Capital and HealthQuest are among the investors financing new eye disease spinout Eyconis. [ABSTRACT FROM AUTHOR]

Interim phase 2 data suggest the prospect can be given safely at the doctor's office, opening up a convenient delivery option for the wet AMD therapy. [ABSTRACT FROM AUTHOR]

Kodiak Sciences gave up on tarcocimab tedromer earlier this year after a pair of phase 3 failures. A fresh batch of late-stage data has changed that. [ABSTRACT FROM AUTHOR]

Annexon's geographic atrophy drug failed to improve lesion growth in phase 2 but did improve vision, which the CEO thinks will support advancement. [ABSTRACT FROM AUTHOR]

Another attempt to take on Regeneron and Bayer's juggernaut Eylea is struggling in the clinic. This time, it's Ribomic's wet age-related macular degeneration (AMD) therapy RBM-007. [ABSTRACT FROM AUTHOR]